A5050809581- CAR-T cell therapy research
- Single-cell and spatial transcriptomics
- Immunotherapy and Immune Responses
- Cell Adhesion Molecules Research
- Cancer Immunotherapy and Biomarkers
- Virus-based gene therapy research
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- Cancer Research and Treatments
- Systemic Lupus Erythematosus Research
- Viral Infectious Diseases and Gene Expression in Insects
- Biosimilars and Bioanalytical Methods
- Galectins and Cancer Biology
- Viral Infections and Immunology Research
- Animal Virus Infections Studies
- Viral gastroenteritis research and epidemiology
- vaccines and immunoinformatics approaches
- Pancreatic and Hepatic Oncology Research
- Integrated Circuits and Semiconductor Failure Analysis
- Peptidase Inhibition and Analysis
- Immune Response and Inflammation
- Nanoplatforms for cancer theranostics
- Plant Virus Research Studies
- Advancements in Semiconductor Devices and Circuit Design
- Urticaria and Related Conditions
Uppsala University
2009-2025
Science for Life Laboratory
2021-2024
Karolinska Institutet
2013-2020
Karolinska University Hospital
2014
Swedish University of Agricultural Sciences
2009-2013
Ludwig Cancer Research
2011
University of Lausanne
2011
Uppsala University Hospital
2005
Kansas State University
2000
Abstract Objective To investigate the release of interferon‐α (IFNα)–inducing material by necrotic or apoptotic cells, its properties, and necessity autoantibodies from systemic lupus erythematosus (SLE) patients for interferogenic activity. Methods U937 monocytic leukemia cells peripheral blood mononuclear (PBMCs) were rendered freeze‐thawing treatment with ultraviolet light. Cell culture supernatants these IgG SLE (SLE IgG) added to cultures normal PBMCs purified plasmacytoid dendritic...
Abstract Objective The etiopathogenesis of primary Sjögren's syndrome (SS) is largely unknown. In other autoimmune diseases, type I interferon (IFN) may play a pivotal role by triggering and sustaining the disease process. We therefore aimed to determine whether patients with SS had an activated IFN system. Methods Salivary gland biopsy specimens sera from were investigated for occurrence IFNα‐producing cells measurable IFNα levels, respectively. ability together apoptotic or necrotic induce...
Abstract Purpose: The chimeric antigen receptor (CAR) T-cell therapy has been effective for patients with CD19+ B-cell malignancies. Most studies have investigated the second-generation CARs either CD28 or 4-1BB costimulatory domains in CAR receptor. Here, we describe first clinical phase I/IIa trial using third-generation T cells targeting CD19 to evaluate safety and efficacy. Patients Methods: Fifteen lymphoma leukemia were treated cells. received chemotherapy during manufacture 11 of 15...
Abstract Objective To investigate the ability of systemic lupus erythematosus (SLE) autoantigen– and Sjögren's syndrome (SS) autoantigen–associated U1 small nuclear RNA (U1 snRNA) hY1RNA to induce interferon‐α (IFNα) production. Methods In vitro–transcribed snRNA or lipofectin were added peripheral blood mononuclear cell (PBMC) cultures. Purified snRNP particles IgG from SLE patients (SLE‐IgG) cultures PBMCs, enriched monocytes, natural interferon–producing cells (NIPCs); latter are also...
<h3>Objectives</h3> To study the presence of interferogenic autoantibodies in systemic sclerosis (SSc) and their correlation with clinical manifestations, serum levels interferon α (IFNα) chemokines importance disease process. <h3>Methods</h3> Peripheral blood mononuclear cells (PBMCs) or purified plasmacytoid dendritic (pDCs) from healthy donors were stimulated sera patients SSc (n=70) individuals (n=30), together necrotic apoptotic cell material. The IFNα produced IFNα, IFN-inducible...
Abstract Objective Interferon‐α (IFNα) is produced in several autoimmune diseases, including systemic lupus erythematosus (SLE), and may be important their pathogenesis. We undertook this study to investigate how IFNα production induced by RNA‐containing immune complexes (ICs) plasmacytoid dendritic cells (PDCs) regulated. Methods Normal PDCs purified from peripheral blood mononuclear (PBMCs) were cocultivated with other cell populations isolated healthy individuals or SLE patients. was ICs,...
Pretreatment of B-cell lymphoma patients with immunostimulatory gene therapy using armed oncolytic viruses may prime tumor lesions for subsequent chimeric antigen receptor (CAR) T-cell therapy, thereby enhancing CAR functionality and possibly increasing response rates in patients. LOAd703 (delolimogene mupadenorepvec) is an adenovirus (serotype 5/35) that encodes the transgenes CD40L 4-1BBL, which activate both antigen-presenting cells T cells. Many adenoviruses failed to demonstrate...
Abstract T‐cells specific for foreign ( e.g. , viral) antigens can give rise to strong protective immune responses, whereas self/tumor antigen‐specific are thought be less powerful. However, synthetic T‐cell vaccines composed of Melan‐A/MART‐1 peptide, CpG and IFA induce high frequencies tumor‐specific CD8 in PBMC melanoma patients. Here we analyzed the functionality these directly ex vivo by multiparameter flow cytometry. The production multiple cytokines (IFNγ, TNFα, IL‐2) upregulation...
Development of T cell-directed immune checkpoint inhibitors (ICI) has revolutionized metastatic melanoma (MM) therapy, but <50% treated patients experience durable responses. This phase I trial (NCT01946373) investigates the safety/feasibility tumor-infiltrating lymphocyte (TIL) adoptive cell therapy (ACT) combined with dendritic (DC) vaccination in MM progressing on ICI.An initial cohort (5 patients) received TIL alone to evaluate safety and allow for optimization expansion protocols. A...
Abstract Gene engineering of the tumor microenvironment (TME) with viral vectors encoding immunostimulatory genes can inflame TME and create basis for an immune response against cells. Adm703 is adenoviral vector based on AdEasy system. encodes two murine genes, trimerized membrane-bound CD40L 4-1BBL that are expressed by all infected cells (tumor stroma). The transgenes induce maturation dendritic expansion memory formation T as well shift general pro-tumorigenic environment towards...
Although CD19 chimeric antigen receptor T cells (CAR-T) therapy has shown remarkable success in B-cell malignancies, a substantial fraction of patients do not obtain long-term clinical response. This could be influenced by the quality individual CAR-T infusion product. To shed some light on this, outcome was correlated to characteristics products.In this phase II study, with lymphoma (n = 23) or leukemia 1) received one two infusions third-generation CD19-directed CAR-Ts (2 × 108/m2). The...
Abstract Immunostimulatory gene therapy using oncolytic viruses is currently evaluated as a promising for cancer aiming to induce anti‐tumour immunity. Here, we investigate the capacity of adenoviruses (LOAd) and their transgenes immunogenicity in infected tumour cells. Oncolysis death‐related markers were assessed after infection eight human solid cell lines with different LOAd expressing trimerized, membrane‐bound (TMZ)‐CD40L, TMZ‐CD40L 41BBL, or no transgenes. The induced transgene...
Dendritic cell (DC) vaccines have been demonstrated to elicit immunological responses in numerous cancer immunotherapy trials. However, long-lasting clinical effects are infrequent. We therefore sought establish a protocol generate DC with greater immunostimulatory capacity. Immature were generated from healthy donor monocytes by culturing the presence of IL-4 and GM-CSF further differentiated into mature addition cocktails containing different cytokines toll-like receptor (TLR) agonists....
Tumor-infiltrating lymphocytes (TIL) are considered enriched for T cells recognizing shared tumor-antigens or mutation-derived neoepitopes. We performed exome sequencing and HLA-A*02:01 epitope prediction from tumor cell lines two HLA-A2 positive melanoma patients whose TIL displayed strong reactivity. The potential neoepitopes were screened recognition using autologous by immunological assays presentation on major histocompatibility complex class I (MHC -I) molecules Poisson detection mass...
Immune checkpoint inhibitors have revolutionized the treatment of metastatic melanoma, but most tumors show resistance. Resistance is connected to a non-T cell inflamed phenotype partially caused by lack functional dendritic cells (DCs) that are crucial for T priming. Herein, we investigated whether adenoviral gene vehicle mLOAd703 carrying both DC- and cell-activating genes can lead inflammation in B16-CD46 model thereby overcome resistance inhibition therapy. were injected subcutaneously...
To find semi-quantitative and quantitative Positron Emission Tomography/Magnetic Resonance (PET/MR) imaging metrics of both tumor non-malignant lymphoid tissue (bone marrow spleen) for Progression Free Survival (PFS) Overall (OS) prediction in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) undergoing Chimeric Antigen Receptor (CAR) T-cell therapy.A single-center prospective study 16 r/r LBCL CD19-targeted CAR therapy. Whole body 18F-fluorodeoxyglucose (FDG) PET/MR...
Interaction studies have suggested that the non-structural protein encoded by open reading frame 3 (ORF3) of porcine circovirus type 2 (PCV2) binds specifically to a regulator G signalling (RGS) related human RGS16 (huRGS16). The full-length clone was generated from cells and sequence analysis revealed close relationship huRGS16 murine RGS16. In vitro pull-down experiments verified an interaction between (poRGS16) ORF3 PCV2. Using GST-linked proteins three different genogroups PCV2 1 (PCV1)...
Abstract Background The activation of dendritic cells (DCs) is pivotal for generating antigen-specific T-cell responses to eradicate tumor cells. Hence, immunotherapies targeting this interplay are especially intriguing. Moreover, it interest modulate the microenvironment (TME), as harsh milieu often impairs adaptive immune responses. Oncolytic viral therapy presents an opportunity overcome immunosuppression in tumors by destroying and thereby releasing antigens immunostimulatory factors....
Abstract Background and aim: Although several drugs have been approved that improve overall survival in patients with metastatic melanoma, there is still a need for additional treatments when the ones are exhausted. Adoptive T-cell therapy (ACT) has reported to induce clinical responses up 70% of stage IV melanoma patients. The aim MAT02 trial investigate toxicity feasibility combined treatment adoptive transfer autologous, tumor-derived T cells or without autologous dendritic cell (DC)...